The FDA is requiring new safety warnings for GLP-1 medications after reviewing evidence of a rare optic nerve condition that can cause permanent vision loss.
The U.S. Food and Drug Administration announced on November 9, 2026, that all GLP-1 receptor agonist medications must carry updated warnings about a rare eye condition that can cause permanent vision loss. The decision affects widely prescribed diabetes and weight-loss medications, including Ozempic, Wegovy, Mounjaro and Zepbound.
The condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), occurs when blood flow to the front of the optic nerve becomes insufficient. It can cause sudden, painless vision loss, usually in one eye, and the damage can be permanent.
The FDA’s decision does not establish that GLP-1 medications directly cause NAION. However, the agency determined that evidence from clinical trials, observational research and safety reports supports warnings about a potential increased risk.
The new information will appear in the Warnings and Precautions section of the affected medications’ prescribing labels. The requirement applies across the GLP-1 drug class, including eligible injectable and oral products.
Which Medications Are Affected?
GLP-1 receptor agonists imitate the effects of a hormone that helps regulate blood sugar and appetite. These medications are widely prescribed for type 2 diabetes, obesity and certain related medical conditions.
The FDA’s decision covers products containing semaglutide, liraglutide, dulaglutide, exenatide and other GLP-1 receptor agonists. It also includes tirzepatide, which acts on both GLP-1 and GIP hormone receptors.
Among the medications affected are Ozempic, Wegovy and Rybelsus, which contain semaglutide and are manufactured by Novo Nordisk. Eli Lilly’s Mounjaro and Zepbound, which contain tirzepatide, are also included.
Other affected brands include Trulicity, Victoza, Saxenda, Soliqua, Xultophy and the oral medication Foundayo. The FDA listed these products in its November 9 safety communication.
Although these drugs share important biological effects, their approved uses differ. Some treat diabetes, others support weight management, and certain products have additional approved uses involving cardiovascular disease, kidney disease or sleep apnea.
The warning is intended to inform patients and medical professionals about a possible safety concern without suggesting that everyone taking these medications will develop an eye problem.
FDA Review Finds Rare Cases of Optic Nerve Damage
The FDA reviewed data from 126 randomized controlled clinical trials involving 134,253 participants. Of those, 78,217 received GLP-1 medications, while 56,036 received a placebo or another type of blood sugar-lowering treatment.
Across the trials, investigators identified 15 probable cases of NAION. Ten occurred among people taking GLP-1 medications, while five occurred among those receiving comparison treatments.
The agency calculated an incidence rate of 6.4 cases per 100,000 person-years among GLP-1 users, compared with 3.8 cases per 100,000 person-years in the comparison group.
A person-year represents one person being followed for one year. Researchers use this measurement because participants may receive treatment for different lengths of time.
The findings suggest a possible increase in risk, but the absolute number of cases remained small. The FDA also emphasized that several factors complicate determining whether the medications themselves are responsible.
Diabetes, high blood pressure, kidney disease and sleep apnea are among the recognized risk factors for NAION. Some of these conditions are already common among people prescribed GLP-1 medications.
That overlap makes it difficult to separate a medication-related effect from the medical conditions that patients have before treatment.
Additional Research Produces Mixed Results
The FDA also examined real-world medical records through its Sentinel surveillance system. The analysis compared adults with type 2 diabetes who began GLP-1 treatment with patients taking other commonly prescribed diabetes medications between 2019 and 2024.
Researchers compared GLP-1 medications with SGLT-2 inhibitors and DPP-4 inhibitors. The results did not show a statistically significant increase in NAION risk when GLP-1 users were compared with patients taking SGLT-2 inhibitors.
However, the comparison with DPP-4 inhibitors found an increased risk. The difference demonstrates why the FDA considered several kinds of evidence rather than relying on one study.
The agency also reviewed published observational studies, reports submitted after medications reached the market and available animal research. Its animal studies did not identify a biological mechanism explaining how GLP-1 drugs might increase the risk.
Although the combined findings supported the warning, they did not resolve every scientific question. Further research may help determine whether certain patients face greater risks or whether individual medications have different safety profiles.
What Patients Should Know About NAION Symptoms
NAION often develops suddenly and without pain. Some patients first notice changes when waking in the morning, while others experience a rapid loss of vision during normal daily activities.
Symptoms can include blurred eyesight, blind spots, tunnel vision, changes in color perception or reduced sharpness in the center of the visual field. The condition generally affects one eye initially.
The World Health Organization has warned that NAION-related vision loss is generally irreversible and that no effective treatment is currently available to restore lost vision. People who experience the condition in one eye also face an increased risk of developing it in the other.
Patients experiencing sudden vision loss or other abrupt visual disturbances should seek urgent medical attention. The FDA advises contacting a healthcare professional immediately and obtaining prompt evaluation by an ophthalmologist when NAION is suspected.
The agency recommends that clinicians consider stopping GLP-1 treatment in patients who develop NAION unless the medical benefits clearly outweigh the risks.
Patients who have previously experienced NAION should discuss the potential risks and benefits of treatment with their prescribing clinician. The FDA has not recommended that every patient discontinue GLP-1 medication because of the new warning.
European Regulators Previously Raised Similar Concerns
The U.S. decision follows an earlier European safety review involving semaglutide. In June 2025, the European Medicines Agency determined that NAION should be classified as a very rare side effect of semaglutide-containing medications.
The European review estimated that the condition could affect up to one in 10,000 people taking semaglutide. Its analysis of population studies suggested approximately one additional NAION case per 10,000 person-years of treatment.
European regulators recommended updating information for Ozempic, Wegovy and Rybelsus. They also advised that patients with confirmed NAION should stop semaglutide treatment.
The WHO subsequently issued a safety communication concerning semaglutide and NAION in June 2025. It highlighted the importance of recognizing sudden visual symptoms and reporting suspected adverse reactions.
The FDA’s latest requirement goes further by applying the warning across the GLP-1 medication class rather than limiting it to semaglutide products.
Drugmakers Respond to Updated Safety Requirements
Novo Nordisk and Eli Lilly acknowledged the FDA’s announcement while emphasizing the importance of evaluating the available evidence.
In a statement reported by ABC News, Novo Nordisk maintained that the research does not establish a cause-and-effect relationship between GLP-1 treatment and NAION. The company said it continues to monitor safety information and remains confident in the benefit-risk profile of its medications.
Eli Lilly said the FDA’s communication applies to medications with GLP-1 receptor activity and does not identify findings specific to Lilly products. The company said it was evaluating the announcement and would respond to the agency.
The reactions reflect an important distinction between identifying a possible safety signal and demonstrating that a drug directly causes a medical condition. Regulators may require precautionary labeling when evidence suggests a meaningful risk, even while scientific questions remain unresolved.
GLP-1 medications provide established benefits for many patients, including improved blood sugar control and clinically significant weight reduction. Some products also reduce the likelihood of serious complications in particular patient groups.
The FDA’s action is intended to help patients and clinicians consider those benefits alongside the newly emphasized eye risk.
The agency will continue collecting adverse-event reports and examining new research as updated warning labels are implemented. Healthcare professionals are being asked to recognize possible NAION symptoms promptly and evaluate affected patients without delay.
IMAGE: Source FDA Building 66 – CDRH Author The U.S. Food and Drug Administration CC0